Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Earnings Call Transcript February 19, 2025Exact Sciences Corporation misses on earnings expectations.
Exact Sciences Corp (EXAS)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 2,360,208 | $132,620,088 | +91% | 0.06% |
| 2. | Armistice Capital Steven Boyd | 1,617,000 | $90,859,230 | 1.23% | |
| 3. | Zevenbergen Capital Investments Nancy Zevenbergen | 1,376,057 | $77,320,643 | -5% | 1.57% |
| 4. | Holocene Advisors Brandon Haley | 897,532 | $50,432,323 | -52% | 0.16% |
| 5. | 40,075,000 | $39,949,766 | +27% | 1.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $51.35 | 19,500 | 1,074,191 | 2024-11-13 | Filing | ||
| $37.71 | 2,500 | Director | 60,858 | 2017-08-17 | Filing | |
| $13.84 | 10,000 | Director | 136,379 | 2016-12-14 | Filing | |
| $18.10 | 5,000 | Director | 121,247 | 2016-09-01 | Filing | |
| $17.93 | 3,380 | Director | 105,927 | 2016-08-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.00 | 929 | 12,758 | 2024-10-08 | Filing | ||
| $70.00 | 929 | 13,687 | 2024-09-18 | Filing | ||
| $60.15 | 67 | 44,644 | 2024-05-01 | Filing | ||
| $60.15 | 136 | 47,042 | 2024-05-01 | Filing | ||
| $60.15 | 30 | 9,866 | 2024-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,753,505 | $1,166,139,452 | 0.06% | |
| 2. | 17,537,617 | $985,438,772 | 0.14% | |
| 3. | 17,020,290 | $956,370,096 | 0.01% | |
| 4. | 12,058,540 | $677,569,362 | 0.12% | |
| 5. | 11,869,962 | $666,973,174 | 0.01% |
News See All
10 Best Genomics Stocks To Buy Right Now
Genomics is the study of genes and how they function.
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Exact Sciences Corporation (NASDAQ:EXAS) Q3 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS) Q3 2024 Earnings Call Transcript November 5, 2024Exact Sciences Corporation reports earnings inline with expectations.
Exact Sciences Corporation (EXAS) Bounced Back in Q3
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Buzzing AI Health Stocks
The economic impact of AI is projected to be substantial, particularly in regions like China and North America, which are expected to see GDP boosts of 26% and 14.5%, respectively, by 2030, amounting ...
Should You Hold Exact Sciences Corporation (EXAS)?
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its second quarter 2024 investor letter. A copy of the fund can be downloaded here.
Should You Believe in the Growth Potential of Exact Sciences Corporation (EXAS)?
Baron Funds, an investment management company, released its “Baron Discovery Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Here’s Why Baron Opportunity Fund Sold its Stake in Exact Sciences Corp (EXAS)
Baron Funds, an investment management company, released its “Baron Opportunity Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences Second Quarter 2024 Earnings Call.
Billionaire Hedge Funds
